A COMPREHENSIVE REVIEW OF CAR-T CELL THERAPY ACROSS RHEUMATIC DISEASES
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.5945Keywords:
CAR-T Cell Therapy, Immunotherapy, Autoimmune Rheumatic Diseases, Systemic Lupus Erythematosus, Rheumatoid Arthritis, Systemic SclerosisAbstract
Background: Autoimmune rheumatic diseases (ARDs) are characterized by a failure of immune tolerance, leading to chronic inflammation, autoantibody production, and progressive organ damage. Conventional therapies often fail to induce long-term, drug-free remission in refractory patients. Chimeric antigen receptor (CAR) T-cell therapy, originally developed for hematological malignancies, has appeared as a promising strategy to achieve the sustained depletion of pathogenic immune cells in rheumatology.
Objective: This review critically synthesizes current evidence regarding the pathophysiological mechanisms, molecular designs, clinical efficacy, and toxicity profiles of CAR-T therapy across systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM), and adult-onset Still's disease (AOSD).
Methods: 77 peer-reviewed sources, including clinical trials, preclinical models, and case series, were analyzed and objectively categorized by target antigens, cellular modifications, and clinical endpoints.
Results: CD19-directed CAR-T cells successfully penetrate inflamed tissues and deplete the autoreactive B-cell compartment, resulting in measurable clinical remission in highly refractory SLE, SSc, and IIM cohorts.This enables the complete discontinuation of concurrent immunosuppressive drugs. Due to a complex, hypoxic synovial microenvironment, targeted RA treatment needs advanced approaches, such as fourth-generation CARs and in vivo generation techniques. Therapy-associated toxicities, primarily cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), generally present with significantly lower clinical severity in ARD patients compared to heavily pre-treated oncological cohorts.
Conclusion: CAR-T cell therapy represents a fundamental paradigm shift in the management of severe ARD, shifting the objective from chronic immunosuppression to definitive immune reconstitution. Despite logistical, financial, and safety challenges, clinical efficacy in treatment-refractory cases remains exceptionally high.
References
Lyu, X., Gupta, L., Tholouli, E., & Chinoy, H. (2023). Chimeric antigen receptor T cell therapy: A new emerging landscape in autoimmune rheumatic diseases. Rheumatology, 63(5), 1206–1216. https://doi.org/10.1093/rheumatology/kead616
Li, Y., & Chen, Z. (2022). Cell-based therapies for rheumatoid arthritis: Opportunities and challenges. Therapeutic Advances in Musculoskeletal Disease, 14. https://doi.org/10.1177/1759720X221100294
Li, Y. R., Lyu, Z., Chen, Y., Fang, Y., & Yang, L. (2024). Frontiers in CAR-T cell therapy for autoimmune diseases. Trends in Pharmacological Sciences, 45(9), 839–857. https://doi.org/10.1016/j.tips.2024.07.005
Zhou, J., Lei, B., Shi, F., Luo, X., Wu, K., Xu, Y., Zhang, Y., Liu, R., Wang, H., Zhou, J., & He, X. (2024). CAR T-cell therapy for systemic lupus erythematosus: Current status and future perspectives. Frontiers in Immunology, 15, Article 1476859. https://doi.org/10.3389/fimmu.2024.1476859
Liu, J., Zhao, Y., & Zhao, H. (2024). Chimeric antigen receptor T-cell therapy in autoimmune diseases. Frontiers in Immunology, 15. https://doi.org/10.3389/fimmu.2024.1492552
Taubmann, J., Müller, F., Yalcin Mutlu, M., Völkl, S., Aigner, M., Bozec, A., Mackensen, A., Grieshaber-Bouyer, R., & Schett, G. (2024). CD19 chimeric antigen receptor T cell treatment: Unraveling the role of B cells in systemic lupus erythematosus. Arthritis & Rheumatology, 76(4), 497–504. https://doi.org/10.1002/art.42784
Saegusa, K., Tsuchida, Y., Komai, T., Tsuchiya, H., & Fujio, K. (2025). Advances in targeted therapy for systemic lupus erythematosus: Current treatments and novel approaches. International Journal of Molecular Sciences, 26(3), Article 929. https://doi.org/10.3390/ijms26030929
Nie, W., Yang, X., Ma, M., Xu, X., & Hou, J. (2025). Chimeric antigen receptor T cell therapy for autoimmune diseases. Current Opinion in Immunology, 95, 102596. https://doi.org/10.1016/j.coi.2025.102596
Schett, G., Müller, F., Taubmann, J., Mackensen, A., Wang, W., Furie, R., Gold, R., Haghikia, A., Merkel, P., Caricchio, R., D’Agostino, M., Locatelli, F., June, C., & Mougiakakos, D. (2024). Advancements and challenges in CAR T cell therapy in autoimmune diseases. Nature Reviews Rheumatology, 20(9), 531–544. https://doi.org/10.1038/s41584-024-01139-z
Alexander, T., & Greco, R. (2022). Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases: Overview and future considerations from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 57(7), 1055–1062. https://doi.org/10.1038/s41409-022-01702-w
Rangel-Peláez, C., Martínez-Gutiérrez, L., Tristán-Manzano, M., Callejas, J., Ortego-Centeno, N., Martín, F., & Martín, J. (2024). CD19 CAR-T cell therapy: A new dawn for autoimmune rheumatic diseases? Frontiers in Immunology, 15. https://doi.org/10.3389/fimmu.2024.1502712
Anyfanti, P., Evangelidis, P., Kotsiou, N., Papakonstantinou, A., Eftychidis, I., Sakellari, I., Dimitroulas, T., & Gavriilaki, E. (2025). Chimeric antigen receptor T cell immunotherapy for autoimmune rheumatic disorders: Where are we now? Cells, 14. https://doi.org/10.3390/cells14161242
Wu, D., Xu-Monette, Z., Zhou, J., Yang, K., Wang, X., Fan, Y., & Young, K. (2025). CAR T-cell therapy in autoimmune diseases: A promising frontier on the horizon. Frontiers in Immunology, 16. https://doi.org/10.3389/fimmu.2025.1613878
Kuipers, M. T., & Kersten, M. J. (2025). CD19-directed chimeric antigen receptor T-cell therapy: What can we learn from the haematologist? Lupus Science & Medicine, 12(1), Article e001157. https://doi.org/10.1136/lupus-2024-001157
Schett, G., Mackensen, A., & Mougiakakos, D. (2023). CAR T-cell therapy in autoimmune diseases. The Lancet. https://doi.org/10.1016/S0140-6736(23)01126-1
Alnefaie, A., Albogami, S., Asiri, Y., Ahmad, T., Alotaibi, S. S., Al-Sanea, M. M., & Althobaiti, H. (2022). Chimeric antigen receptor T-cells: An overview of concepts, applications, limitations, and proposed solutions. Frontiers in Bioengineering and Biotechnology, 10, Article 797440. https://doi.org/10.3389/fbioe.2022.797440
Patel, K. K., Tariveranmoshabad, M., Kadu, S., Shobaki, N., & June, C. (2025). From concept to cure: The evolution of CAR-T cell therapy. Molecular Therapy, 33(5), 2123–2140. https://doi.org/10.1016/j.ymthe.2025.03.005
Doglio, M., Alexander, T., Del Papa, N., Snowden, J., & Greco, R. (2022). New insights in systemic lupus erythematosus: From regulatory T cells to CAR-T-cell strategies. The Journal of Allergy and Clinical Immunology, 150(5), 1019–1021. https://doi.org/10.1016/j.jaci.2022.08.003
Kalliolias, G., Basdra, E., & Papavassiliou, A. (2025). Chimeric antigen receptor (CAR) therapies for precise eradication of pathogenic cells in autoimmunity. Arthritis Research & Therapy, 28. https://doi.org/10.1186/s13075-025-03711-8
Chasov, V., Zmievskaya, E., Ganeeva, I., Gilyazova, E., Davletshin, D., Khaliulin, M., Kabwe, E., Davidyuk, Y. N., Valiullina, A., Rizvanov, A., & Bulatov, E. (2024). Immunotherapy strategy for systemic autoimmune diseases: Betting on CAR-T cells and antibodies. Antibodies, 13(1), Article 10. https://doi.org/10.3390/antib13010010
Franco-Fuquen, P., Figueroa-Aguirre, J., Martínez, D., Moreno-Cortes, E., Garcia-Robledo, J., Vargas-Cely, F., Castro-Martínez, D., Almaini, M., & Castro, J. (2024). Cellular therapies in rheumatic and musculoskeletal diseases. Journal of Translational Autoimmunity, 10, Article 100264. https://doi.org/10.1016/j.jtauto.2024.100264
Freeley, M. (2025). CAR T cell therapy for rheumatoid arthritis. Clinical Reviews in Allergy & Immunology, 68. https://doi.org/10.1007/s12016-025-09113-7
Ellebrecht, C., Bhoj, V., Nace, A., Choi, E., Mao, X., Cho, M., Di Zenzo, G., Lanzavecchia, A., Seykora, J., Cotsarelis, G., Milone, M., & Payne, A. (2016). Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science, 353(6295), 179–184. https://doi.org/10.1126/science.aaf6756
Boroughs, A., Larson, R., Choi, B., Bouffard, A., Riley, L., Schiferle, E., Kulkarni, A., Cetrulo, C., Ting, D., Blazar, B., Demehri, S., & Maus, M. (2019). Chimeric antigen receptor costimulation domains modulate human regulatory T cell function. JCI Insight, 5(8). https://doi.org/10.1172/jci.insight.126194
Tur, C., Eckstein, M., Velden, J., Rauber, S., Bergmann, C., Auth, J., Bucci, L., Corte, G., Hagen, M., Wirsching, A., Grieshaber-Bouyer, R., Reis, P., Kittan, N., Wacker, J., Rius Rigau, A., Ramming, A., D’Agostino, M. A., Hartmann, A., . . . Raimondo, M. G. (2025). CD19-CAR T-cell therapy induces deep tissue depletion of B cells. Annals of the Rheumatic Diseases, 84(1), 106–114. https://doi.org/10.1136/ard-2024-226142
Mougiakakos, D., Krönke, G., Völkl, S., Kretschmann, S., Aigner, M., Kharboutli, S., Böltz, S., Manger, B., Mackensen, A., & Schett, G. (2021). CD19-targeted CAR T cells in refractory systemic lupus erythematosus. The New England Journal of Medicine, 385(6), 567–569. https://doi.org/10.1056/NEJMc2107725
Müller, F., Hagen, M., Wirsching, A., et al. (2026). CD19 CAR-T cells for treatment-refractory autoimmune diseases: The phase 1/2 CASTLE basket trial. Nature Medicine, 32, 1142–1150. https://doi.org/10.1038/s41591-025-04185-6
Wilhelm, A., Chambers, D., Müller, F., Bozec, A., Grieshaber-Bouyer, R., Winkler, T., Mougiakakos, D., Mackensen, A., Schett, G., & Krönke, G. (2024). Selective CAR T cell–mediated B cell depletion suppresses IFN signature in SLE. JCI Insight, 9(12). https://doi.org/10.1172/jci.insight.179433
Groener, M., & Paik, J. J. (2025). Emerging B and plasma cell-targeting immune therapies in idiopathic inflammatory myopathies. Frontiers in Immunology, 16, Article 1581323. https://doi.org/10.3389/fimmu.2025.1581323
Wang, W., He, S., Zhang, W., Zhang, H., DeStefano, V. M., Wada, M., Pinz, K., Deener, G., Shah, D., Hagag, N., Wang, M., Hong, M., Zeng, R., Lan, T., Ma, Y., Li, F., Liang, Y., Guo, Z., Zou, C., . . . Yuan, Y. (2024). BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: A phase 1 open-label clinical trial. Annals of the Rheumatic Diseases, 83(10), 1304–1314. https://doi.org/10.1136/ard-2024-225785
Dao, L., Vũ, T., Nguyen, Q., Hoang, V., & Nguyen, T. (2024). Current cell therapies for systemic lupus erythematosus. Stem Cells Translational Medicine, 13(9), 859–872. https://doi.org/10.1093/stcltm/szae044
Dingfelder, J., Taubmann, J., Von Heydebrand, F., Aigner, M., Bergmann, C., Knitza, J., Park, S., Cheng, J., Van Blarcom, T., Schett, G., Mackensen, A., & Lutzny-Geier, G. (2025). Exploring CAR T-cell dynamics: Balancing potent cytotoxicity and controlled inflammation in CAR T-cells derived from systemic sclerosis and myositis patients. International Journal of Molecular Sciences, 26(2), Article 467. https://doi.org/10.3390/ijms26020467
Doglio, M., Ugolini, A., Bercher-Brayer, C., Camisa, B., Toma, C., Norata, R., Del Rosso, S., Greco, R., Ciceri, F., Sanvito, F., Casucci, M., Manfredi, A. A., & Bonini, C. (2024). Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in systemic lupus erythematosus. Nature Communications, 15(1), Article 2542. https://doi.org/10.1038/s41467-024-46448-9
Legato, L., Bisio, M., Fasano, F., Benevolo Savelli, C., Secreto, C., Dellacasa, C. M., Botto, B., Busca, A., Cerrano, M., Freilone, R., & Novo, M. (2025). Mechanisms of resistance to CAR T-cells and how to overcome them. Methods and Protocols, 8(5), 108. https://doi.org/10.3390/mps8050108
Brudno, J. N., & Kochenderfer, J. N. (2024). Current understanding and management of CAR T cell-associated toxicities. Nature Reviews Clinical Oncology, 21(7), 501–521. https://doi.org/10.1038/s41571-024-00903-0
Rejeski, K., Jain, M. D., Shah, N. N., Perales, M. A., & Subklewe, M. (2024). Immune effector cell-associated haematotoxicity after CAR T-cell therapy: From mechanism to management. The Lancet Haematology, 11(6), e459–e470. https://doi.org/10.1016/S2352-3026(24)00077-2
Schubert, M. L., Schmitt, M., Wang, L., Ramos, C. A., Jordan, K., Müller-Tidow, C., & Dreger, P. (2021). Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Annals of Oncology, 32(1), 34–48. https://doi.org/10.1016/j.annonc.2020.10.478
Gómez-Puerta, J., Monegal, A., Ponce, A., Peris, P., Martínez-Cibrian, N., Sarmiento-Monroy, J., Ortiz-Maldonado, V., Triguero, A., De Larrea, C., Delgado, J., García-Herrera, A., Albero-González, R., Bosch-Amate, X., Español-Rego, M., González, A., Sanmartí, R., & Juan, M. (2024). Rheumatologic complications of CAR-T cell therapy: Experience of a single center. Seminars in Arthritis and Rheumatism, 71, Article 152610. https://doi.org/10.1016/j.semarthrit.2024.152610
Müller, F., Taubmann, J., Bucci, L., Wilhelm, A., Bergmann, C., Völkl, S., Aigner, M., Rothe, T., Minopoulou, I., Tur, C., Knitza, J., Kharboutli, S., Kretschmann, S., Vasova, I., Spoerl, S., Reimann, H., Munoz, L., Gerlach, R. G., Schäfer, S., . . . Schett, G. (2024). CD19 CAR T-cell therapy in autoimmune disease: A case series with follow-up. The New England Journal of Medicine, 390(8), 687–700. https://doi.org/10.1056/NEJMoa2308917
Kattamuri, L., Lal, B., Vojjala, N., Jain, M., Sharma, K., Jain, S., & Hadidi, S. (2025). Safety and efficacy of CAR-T cell therapy in patients with autoimmune diseases: A systematic review. Rheumatology International, 45. https://doi.org/10.1007/s00296-024-05772-5
Cordas Dos Santos, D. M., Tix, T., Shouval, R., Gafter-Gvili, A., Alberge, J. B., Cliff, E. R. S., Theurich, S., von Bergwelt-Baildon, M., Ghobrial, I. M., Subklewe, M., Perales, M. A., & Rejeski, K. (2024). A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy. Nature Medicine, 30(9), 2667–2678. https://doi.org/10.1038/s41591-024-03084-6
Lefebvre, B., Kang, Y., Smith, A. M., Frey, N. V., Carver, J. R., & Scherrer-Crosbie, M. (2020). Cardiovascular effects of CAR T cell therapy: A retrospective study. JACC: CardioOncology, 2(2), 193–203. https://doi.org/10.1016/j.jaccao.2020.04.012
Hagen, M., Müller, F., Wirsching, A., Kharboutli, S., Spoerl, S., Düsing, C., Krickau, T., Metzler, M., Völkl, S., Aigner, M., Kretschmann, S., Vasova, I., Saake, M., Schliep, S., Kubacki, T., Hunzelmann, N., Bucci, L., Taubmann, J., Bergmann, C., . . . Schett, G. (2023). Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: An observational study. The Lancet Rheumatology. https://doi.org/10.1016/S2665-9913(25)00091-8
Jin, X., Xu, Q., Pu, C., Zhu, K., Lu, C., Jiang, Y., Xiao, L., Han, Y., & Lu, L. (2021). Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus. Cellular & Molecular Immunology, 18(8), 1896–1903. https://doi.org/10.1038/s41423-020-0472-1
Kansal, R., Richardson, N., Neeli, I., Khawaja, S., Chamberlain, D., Ghani, M., Ghani, Q. U., Balazs, L., Beranova-Giorgianni, S., Giorgianni, F., Kochenderfer, J. N., Marion, T., Albritton, L. M., & Radic, M. (2019). Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Science Translational Medicine, 11(482), Article eaav1648. https://doi.org/10.1126/scitranslmed.aav1648
Friedberg, E., Wohlfarth, P., Schiefer, A., Skrabs, C., Pickl, W., Worel, N., Staber, P., Jäger, U., & Ay, C. (2024). Disappearance of antiphospholipid antibodies after anti-CD19 CAR T-cell therapy of B-cell lymphoma in a patient with systemic lupus erythematosus and antiphospholipid syndrome. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2024.09.024
Meroni, P., Capobianco, E., & Tedesco, F. (2025). Can we cure antiphospholipid syndrome? Current Opinion in Immunology, 96, Article 102610. https://doi.org/10.1016/j.coi.2025.102610
Blagov, A. V., Pleshko, E. M., Maltseva, O. N., Asoyan, A. Z., Ravani, A. L., & Orekhov, A. N. (2025). CAR-T cell therapy for rheumatoid arthritis: Current status and molecular insights. Cellular and Molecular Biology, 71(6), 80–88. https://doi.org/10.14715/cmb/2025.71.6.11
Li, Y., Li, S., Zhao, X., Sheng, J., Xue, L., Schett, G., Shi, C., Hu, B., Wang, X., & Chen, Z. (2025). Fourth-generation chimeric antigen receptor T-cell therapy is tolerable and efficacious in treatment-resistant rheumatoid arthritis. Cell Research, 35(3), 220–223. https://doi.org/10.1038/s41422-024-01068-2
Avouac, J., & Scherlinger, M. (2024). CAR T-cell therapy for rheumatic diseases: What does the future hold? BioDrugs, 39, 5–19. https://doi.org/10.1007/s40259-024-00692-z
Zhang, B., Wang, Y., Yuan, Y., Sun, J., Liu, L., Huang, D., Hu, J., Wang, M., Li, S., Song, W., Chen, H., Zhou, D., & Zhang, X. (2020). In vitro elimination of autoreactive B cells from rheumatoid arthritis patients by universal chimeric antigen receptor T cells. Annals of the Rheumatic Diseases, 80(2), 176–184. https://doi.org/10.1136/annrheumdis-2020-217844
Whittington, K., Prislovsky, A., Beaty, J., Albritton, L., Radic, M., & Rosloniec, E. (2022). CD8+ T cells expressing an HLA-DR1 chimeric antigen receptor target autoimmune CD4+ T cells in an antigen-specific manner and inhibit the development of autoimmune arthritis. The Journal of Immunology, 208(1), 16–26. https://doi.org/10.4049/jimmunol.2100643
Orvain, C., Boulch, M., Bousso, P., Allanore, Y., & Avouac, J. (2021). Is there a place for chimeric antigen receptor–T cells in the treatment of chronic autoimmune rheumatic diseases? Arthritis & Rheumatology, 73. https://doi.org/10.1002/art.41812
Liang, S., Zhou, S., Zeng, Y., Chen, Y., Sun, Y., Xiao, Z., Zhao, G., Xu, C., & Lai, P. (2026). T-cell-targeted fusogenic nanovesicles generate CAR-T cells in vivo for rheumatoid arthritis therapy. Biomarker Research, 14. https://doi.org/10.1186/s40364-026-00905-3
Liang, Z., Xie, H., & Wu, D. (2025). Immune mediated inflammatory diseases: Moving from targeted biologic therapy, stem cell therapy to targeted cell therapy. Frontiers in Immunology, 16. https://doi.org/10.3389/fimmu.2025.1520063
Segovia, M., Landoni, D., Defranchi, Y., Jofré, R., Olivares, C., & Keppeke, G. (2025). A new therapeutic pathway in autoimmune diseases: Chimeric antigen receptor T cells (CAR-T) targeting specific cell subtypes or antigen-specific B lymphocytes—a brief review. Exploration of Immunology. https://doi.org/10.37349/ei.2025.1003185
Szabo, D., Balogh, A., Gopcsa, L., Giba-Kiss, L., Lakatos, G., Paksi, M., Réti, M., Takács, P., Heteren, P., Zadoyan, G., Holtkamp, S., Overstijns, T., Miltenyi, S., Remenyi, P., & Nagy, G. (2024). Sustained drug-free remission in rheumatoid arthritis associated with diffuse large B-cell lymphoma following tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy using zamtocabtagene autoleucel. RMD Open, 10. https://doi.org/10.1136/rmdopen-2024-004727
Haghikia, A., Hegelmaier, T., Wolleschak, D., Böttcher, M., Pappa, V., Motte, J., Borie, D., Gold, R., Feist, E., Schett, G., & Mougiakakos, D. (2024). Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis. Annals of the Rheumatic Diseases, 83, 1597–1598. https://doi.org/10.1136/ard-2024-226017
Zulfiqar, F., Shahzad, M., Amin, M., Vyas, A., Sarfraz, Z., Zainab, A., Qasim, H., Kaur, D., Khavandgar, N., Lutfi, F., Hematti, P., Mcguirk, J., & Mushtaq, M. (2024). Outcomes with chimeric antigen receptor T-cell therapy in rheumatological disorders: A systematic review. Transplant Immunology, 102137. https://doi.org/10.1016/j.trim.2024.102137
Patil, H., Bharadwaj, R., Dutta, N., Subramanian, R., Prasad, S., & Mamadapur, M. (2025). CAR-T cell therapy in rheumatic diseases: A review article. Clinical Rheumatology. https://doi.org/10.1007/s10067-025-07451-7
Bergmann, C., Müller, F., Distler, J. H. W., Györfi, A. H., Völkl, S., Aigner, M., Kretschmann, S., Reimann, H., Harrer, T., Bayerl, N., Boeltz, S., Wirsching, A., Taubmann, J., Rösler, W., Spriewald, B., Wacker, J., Atzinger, A., Uder, M., Kuwert, T., . . . Schett, G. (2023). Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells. Annals of the Rheumatic Diseases, 82(8), 1117–1120. https://doi.org/10.1136/ard-2023-223952
Auth, J., Müller, F., Völkl, S., Bayerl, N., Distler, J., Tur, C., Raimondo, M., Fakhouri, C., Atzinger, A., Coppers, B., Eckstein, M., Liphardt, A., Bäuerle, T., Tascilar, K., Aigner, M., Kretschmann, S., Wirsching, A., Taubmann, J., Hagen, M., . . . Bergmann, C. (2024). CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: A case series. The Lancet Rheumatology. https://doi.org/10.1016/S2665-9913(24)00282-0
Avouac, J., Cauvet, A., Orvain, C., Boulch, M., Tilotta, F., Tu, L., Thuillet, R., Ottaviani, M., Guignabert, C., Bousso, P., & Allanore, Y. (2023). Effects of B cell depletion by CD19-targeted chimeric antigen receptor T cells in a murine model of systemic sclerosis. Arthritis & Rheumatology, 76. https://doi.org/10.1002/art.42677
Pecher, A. C., Hensen, L., Klein, R., Schairer, R., Lutz, K., Atar, D., Seitz, C., Stanger, A., Schneider, J., Braun, C., Schmidt, M., Horger, M., Bornemann, A., Faul, C., Bethge, W., Henes, J., & Lengerke, C. (2023). CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome. JAMA, 329(24), 2154–2162. https://doi.org/10.1001/jama.2023.8753
Nicolai, R., Merli, P., Moran Alvarez, P., Bracaglia, C., Del Bufalo, F., Marasco, E., Caiello, I., Prencipe, G., Algeri, M., Cefalo, M. G., Becilli, M., Quintarelli, C., Sinibaldi, M., Hanssens, L., De Benedetti, F., & Locatelli, F. (2024). Autologous CD19-targeting CAR T cells in a patient with refractory juvenile dermatomyositis. Arthritis & Rheumatology, 76(10), 1560–1565. https://doi.org/10.1002/art.42933
Wischnewski, S., Rausch, H., Ikenaga, C., Leipe, J., Lloyd, T., & Schirmer, L. (2025). Emerging mechanisms and therapeutics in inflammatory muscle diseases. Trends in Pharmacological Sciences. https://doi.org/10.1016/j.tips.2025.01.005
Aggarwal, A., Almackenzie, M., & Aggarwal, R. (2025). Role of CD19 chimeric antigen receptor T cell therapy in idiopathic inflammatory myopathies. The Journal of Rheumatology, 52(6), 532–542. https://doi.org/10.3899/jrheum.2024-1115
Taubmann, J., Knitza, J., Müller, F., Völkl, S., Aigner, M., Kleyer, A., Gary, R., Kretschmann, S., Boeltz, S., Atzinger, A., Kuwert, T., Roemer, F., Uder, M., Mackensen, A., & Schett, G. (2023). Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies. Rheumatology, 63, e12–e14. https://doi.org/10.1093/rheumatology/kead330
Müller, F., Wirsching, A., Hagen, M., Völkl, S., Tur, C., Raimondo, M. G., Taubmann, J., Bucci, L., Zhang, L., Kretschmann, S., Aigner, M., Eckstein, M., Spörl, S., Kharboutli, S., Böltz, S., Atzinger, A., Munoz, L., Schett, G., Mackensen, A., & Grieshaber-Bouyer, R. (2025). BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells. Nature Medicine, 31(6), 1793–1797. https://doi.org/10.1038/s41591-025-03718-3
Ma, Y., Meng, J., Jia, J., Wang, M., Teng, J., Zhu, D., Yang, C., & Hu, Q. (2021). Current and emerging biological therapy in adult-onset Still’s disease. Rheumatology, 60, 3986–4000. https://doi.org/10.1093/rheumatology/keab485
Tomaras, S., Goetzke, C., Kallinich, T., & Feist, E. (2021). Adult-onset Still’s disease: Clinical aspects and therapeutic approach. Journal of Clinical Medicine, 10. https://doi.org/10.3390/jcm10040733
Feist, E., Mitrovic, S., & Fautrel, B. (2018). Mechanisms, biomarkers and targets for adult-onset Still’s disease. Nature Reviews Rheumatology, 14, 603–618. https://doi.org/10.1038/s41584-018-0081-x
McGonagle, D., Ramanan, A., & Bridgewood, C. (2021). Immune cartography of macrophage activation syndrome in the COVID-19 era. Nature Reviews Rheumatology, 17, 145–157. https://doi.org/10.1038/s41584-020-00571-1
Liu, Y., Dong, M., Chu, Y., Zhou, L., You, Y., Pang, X., Yang, S., Zhang, L., Chen, L., Zhu, L., Xiao, J., Wang, W., Qin, C., & Tian, D. (2024). Dawn of CAR-T cell therapy in autoimmune diseases. Chinese Medical Journal, 137, 1140–1150. https://doi.org/10.1097/CM9.0000000000003111
Cheever, A., Kang, C., Neill, K., Weber, K., Nunez-Cruz, S., & Rui, X. (2024). Application of novel CAR technologies to improve treatment of autoimmune disease. Frontiers in Immunology, 15. https://doi.org/10.3389/fimmu.2024.1465191
Lungova, K., & Putman, M. (2024). Barriers to CAR T-cell therapy in rheumatology. The Lancet Rheumatology. https://doi.org/10.1016/S2665-9913(24)00240-6
Shargh, M., Mahmoudi, M., Agah, S., Forouzanfar, F., Javanmardi, Z., Fadaee, A., Haghmorad, D., & Esmaeili, S. (2025). CAR T-cell therapy in autoimmune diseases: Opportunities and challenges, with implications for RA. Tissue & Cell, 98, Article 103164. https://doi.org/10.1016/j.tice.2025.103164
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Mateusz Miluski, Dorota Szydłowska, Mikołaj Jońca, Natasza Kurys, Adam Kubisa, Aleksandra Dybcio, Szymon Paruszewski, Julia Kupczak, Mikhail Kazachok, Katarzyna Kupczyk
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
